Interview with Professor Stephen Powis

The video discusses the significant milestone in the UK's vaccination program with the introduction of the Moderna vaccine. It highlights the progress made with over 27 million first doses and 6 million second doses administered. The Moderna vaccine will complement existing vaccines and is particularly suitable for adults aged 18-29. Initially deployed in larger centers, its use will expand as supply increases. The Moderna vaccine offers logistical advantages over Pfizer, being easier to store and distribute. The UK has ordered 17 million doses, ensuring the program remains on track to vaccinate all adults by summer.

What milestone has been achieved in the vaccination program according to the text?

What are the age groups for which the Moderna vaccine is particularly recommended as an alternative?

What logistical advantages does the Moderna vaccine have over the Pfizer vaccine?

How many doses of the Moderna vaccine has the UK ordered?

What is the expected timeline for offering the vaccine to adults?